|
gptkbp:instanceOf
|
gptkb:drug
angiotensin II receptor blocker
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:Switzerland
|
|
gptkbp:ATCCode
|
C09CA03
|
|
gptkbp:bioavailability
|
25%
|
|
gptkbp:brand
|
gptkb:Diovan
gptkb:Prexxartan
|
|
gptkbp:CASNumber
|
137862-53-4
|
|
gptkbp:category
|
antihypertensive agent
cardiovascular drug
tetrazole derivative
|
|
gptkbp:chemicalFormula
|
C24H29N5O3
|
|
gptkbp:combines
|
gptkb:amlodipine
gptkb:hydrochlorothiazide
gptkb:sacubitril
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
bilateral renal artery stenosis
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
valsartan
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
gptkb:aliskiren
lithium
potassium-sparing diuretics
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks angiotensin II type 1 receptor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
435.52 g/mol
|
|
gptkbp:patentExpired
|
2012
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
94–97%
|
|
gptkbp:PubChem_CID
|
DB00177
|
|
gptkbp:riskFactor
|
hypotension
renal impairment
angioedema
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
hyperkalemia
|
|
gptkbp:synonym
|
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
|
|
gptkbp:UNII
|
80M03YXJ7I
|
|
gptkbp:usedFor
|
treatment of heart failure
treatment of hypertension
post-myocardial infarction therapy
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Diovan
gptkb:Entresto
gptkb:Exforge
|
|
gptkbp:bfsLayer
|
5
|